Targeting Stat3 in Hepatocellular Carcinoma with Aberrant TGF-b Signaling

Aiwu Ruth He,Gang Li,Rupen Amin,Wilma Jogunoori,John L. Marshall,Michael Zasloff,Lopa Mishra
IF: 11.2
2008-01-01
Cancer Research
Abstract:2377 Hepatocellular Carcinoma (HCC) is the third leading cause of cancer death worldwide, yet there still remain only a few effective therapeutic options for advanced disease. At least 40% of HCCs are clonal and thought to arise from liver progenitor/stem cell transformation, and requiring activation of stem cell renewal factors such as Stat3, Nanog, Oct 3/4. We have found that these HCCs frequently develop in the setting of inactivated TGF-β signaling (Science, 2005, 310(5745):68-71, Oncogene 2007, 26(50):7103-10). The Aims of this study were to expand on our understanding of the intracellular signaling pathways activated in HCC, and to develop new therapeutics targeting HCC-specific signaling pathways. Methods and Results: 1. IL6/Stat3 activity, is markedly increased in 9/10 human HCC tissues and growth of HCC cell lines could be inhibited with the Stat3 inhibitor, NSC 74859. 2. A method was developed to isolate putative HCC progenitor/stem cells, for the purpose of characterizing their response to potential therapeutics. Progenitor/stem cells were isolated from the HCC cell line, Huh7 utilizing antibodies to the stem cell surface marker CD133. We found that CD133+ Huh7 cells differ from CD133- cells with their ability of forming colonies on soft agar with as few as five cells and expression of other stem cell surface markers (Oct4, CD44). 3. These CD133+ cells are more resistant to doxorubicin compared to CD133- cells, consistent with the known resistance of HCC to this agent, yet these CD133+ cells are highly sensitive to Stat3 inhibition. 4. Exposure of CD133+ HCC cells to the Stat3 inhibitor resulted in significant growth suppression, with the most potent effects observed in those lines lacking a functional TGF-β pathway. Conclusion: Inhibiting IL-6/Stat3, a major signaling pathway in HCC stem cell renewal and proliferation might provide a new approach to the targeted treatment of certain forms of HCC.
What problem does this paper attempt to address?